PODD - Insulet Corporation

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
96.74
-0.44 (-0.45%)
As of 2:09PM EDT. Market open.
Stock chart is not supported by your current browser
Previous Close97.18
Open98.19
Bid96.66 x 1300
Ask96.69 x 900
Day's Range96.30 - 98.62
52 Week Range70.80 - 108.91
Volume531,150
Avg. Volume735,998
Market Cap5.735B
Beta (3Y Monthly)1.10
PE Ratio (TTM)1,934.80
EPS (TTM)0.05
Earnings DateMay 1, 2019 - May 6, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est103.73
Trade prices are not sourced from all markets
  • Markit6 hours ago

    See what the IHS Markit Score report has to say about Insulet Corp.

    Insulet Corp NASDAQ/NGS:PODDView full report here! Summary * Bearish sentiment is high Bearish sentimentShort interest | NegativeShort interest is high for PODD with between 15 and 20% of shares on loan. This means that investors who seek to profit from falling equity prices are currently targeting PODD. However, the last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment. Money flowETF/Index ownership | NeutralETF activity is neutral. ETFs that hold PODD had net inflows of $2.58 billion over the last one-month. While these are not among the highest inflows of the last year, the rate of inflow is increasing. Economic sentimentPMI by IHS Markit | NeutralAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is weak relative to the trend shown over the past year, however. Credit worthinessCredit default swapCDS data is not available for this security.Please send all inquiries related to the report to score@ihsmarkit.com.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.

  • 3 Top Healthcare Stocks to Buy in March
    Motley Fool10 days ago

    3 Top Healthcare Stocks to Buy in March

    Find out why our Motley Fool contributors called out these three businesses as top opportunities right now.

  • Why Diabetes Stock Insulet Jumped 15.7% in February
    Motley Fool23 days ago

    Why Diabetes Stock Insulet Jumped 15.7% in February

    The leader in tubeless insulin pump technology acheived full-year profitability for the first time in 2018.

  • Thomson Reuters StreetEvents25 days ago

    Edited Transcript of PODD earnings conference call or presentation 25-Feb-19 9:30pm GMT

    Q4 2018 Insulet Corp Earnings Call

  • How Do Insulet Corporation’s (NASDAQ:PODD) Returns Compare To Its Industry?
    Simply Wall St.26 days ago

    How Do Insulet Corporation’s (NASDAQ:PODD) Returns Compare To Its Industry?

    Today we'll evaluate Insulet Corporation (NASDAQ:PODD) to determine whether it could have potential as an investment idea. Specifically, we're going to calculate its Return On Capital Employed (ROCE), in theRead More...

  • Insulet (PODD) Beats Earnings and Revenue Estimates in Q4
    Zacks27 days ago

    Insulet (PODD) Beats Earnings and Revenue Estimates in Q4

    The year-over-year improvement in Insulet's (PODD) Q4 results on solid uptake of Omnipod system in the United States is encouraging. The company also gains from direct European operations.

  • Insulet Posts Positive Earnings for the Second Consecutive Quarter
    Motley Fool28 days ago

    Insulet Posts Positive Earnings for the Second Consecutive Quarter

    In the fourth quarter, the tubeless insulin pump specialist grew revenue 26% year over year.

  • Insulet (PODD) Q4 2018 Earnings Conference Call Transcript
    Motley Fool28 days ago

    Insulet (PODD) Q4 2018 Earnings Conference Call Transcript

    PODD earnings call for the period ending December 31, 2018.

  • Business Wire29 days ago

    Insulet Reports Fourth Quarter 2018 Revenue of $164.9 Million, Up 26% Year-Over-Year, and Full Year 2018 Revenue of $563.8 Million, Up 22%

    Insulet Corporation , the global leader in tubeless insulin pump technology with its Omnipod® Insulin Management System , today announced financial results for the three months and full year ended December 31, 2018.

  • ACCESSWIRE29 days ago

    Insulet Corporation to Host Earnings Call

    NEW YORK, NY / ACCESSWIRE / February 25, 2019 / Insulet Corporation (NASDAQ: PODD ) will be discussing their earnings results in their 2018 Fourth Quarter Earnings to be held on February 25, 2019 at 4:30 ...

  • Business Wirelast month

    Insulet to Present at Upcoming Investor Conferences

    Insulet Corporation , the global leader in tubeless insulin pump technology with its Omnipod® Insulin Management System, today announced that management wil

  • Insulet (PODD) Reports Next Week: Wall Street Expects Earnings Growth
    Zackslast month

    Insulet (PODD) Reports Next Week: Wall Street Expects Earnings Growth

    Insulet (PODD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

  • 3 Top Diabetes Stocks to Watch in February
    Motley Foollast month

    3 Top Diabetes Stocks to Watch in February

    Innovative insulin pumps and promising drugs make these three companies worthy of investors' attention.

  • Mariko Gordon's Top 5 New Buys for the 4th Quarter
    GuruFocus.comlast month

    Mariko Gordon's Top 5 New Buys for the 4th Quarter

    Daruma Capital Management leader Mariko Gordon (Trades, Portfolio) disclosed she established seven new positions when she released her fourth-quarter 2018 portfolio earlier this week. Warning! GuruFocus has detected 1 Warning Sign with TNDM. Based on these criteria, Gordon's top five new buys for the quarter were Tandem Diabetes Care Inc. (TNDM), Macom Technology Solutions Holdings Inc. (MTSI), Insulet Corp. (PODD), LHC Group Inc. (LHCG) and Cloudera Inc. (CLDR).

  • GlobeNewswire2 months ago

    Market Trends Toward New Normal in IHS Markit, KB Home, Insulet, Booking, Diebold Nixdorf, and Seritage Growth Properties — Emerging Consolidated Expectations, Analyst Ratings

    NEW YORK, Feb. 07, 2019 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.

  • Business Wire2 months ago

    Insulet Appoints Corinne Nevinny to Board of Directors

    Insulet Corporation (PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® Insulin Management System (Omnipod System), today announced that Corinne Nevinny has been appointed to the Company’s Board of Directors, effective immediately. Ms. Nevinny replaces James Mullen, who is stepping down from Insulet’s Board to focus on his family’s philanthropic foundation and other business ventures. Ms. Nevinny is the General Partner of LMNVC, a seed venture fund making early-round investments in start-up companies that have products or services that improve quality of life, including health and wellness oriented businesses.

  • Business Wire2 months ago

    Insulet to Announce Fourth Quarter and Full Year 2018 Financial Results on February 25, 2019

    Insulet Corporation (PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® Insulin Management System, today announced plans to release its financial results for the fourth quarter and full year of 2018 on February 25, 2019 after the close of the financial markets. You may also access the live call by dialing (844) 831-3022 for domestic callers or (315) 625-6887 for international callers, passcode is 7262247. Insulet Corporation (PODD), headquartered in Massachusetts, is an innovative medical device company dedicated to making the lives of people with diabetes and other conditions easier through the use of its Omnipod product platform.

  • ACCESSWIRE2 months ago

    Today's Research Reports on Trending Tickers: Tandem Diabetes Care and Insulet Corporation

    NEW YORK, NY / ACCESSWIRE / January 25, 2019 / U.S. equities were mixed on Thursday as stronger-than-expected quarterly earnings werent enough to outweigh concerns of a global economic slowdown. The Dow ...

  • 3 Top Mid-Cap Stocks to Buy Right Now
    Motley Fool2 months ago

    3 Top Mid-Cap Stocks to Buy Right Now

    Here's why these mid-cap stocks could be about to become large-cap stocks.

  • Here's What Caused Tandem Diabetes Stock to Gain a Jaw-Dropping 1,509% in 2018
    Motley Fool3 months ago

    Here's What Caused Tandem Diabetes Stock to Gain a Jaw-Dropping 1,509% in 2018

    This insulin pump maker launched a revolutionary new treatment option for type 1 patients.

  • Business Wire3 months ago

    Insulet Appoints Wayde McMillan Chief Financial Officer

    Insulet Corporation (PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® Insulin Management System (Omnipod System), today announced that Wayde McMillan has been appointed Executive Vice President and Chief Financial Officer, effective March 1, 2019, succeeding Michael Levitz. To ensure a smooth and successful transition, Mr. McMillan will join the Company in February and Mr. Levitz will continue with the Company in an advisory capacity for a period following the succession effective date.

  • Here's Why Tandem Diabetes Care Is Dropping Today
    Motley Fool3 months ago

    Here's Why Tandem Diabetes Care Is Dropping Today

    Shares tumble on a slow news day. What can explain the double-digit move?